今日の臨床サポート 今日の臨床サポート

著者: 宮川めぐみ 医療法人誠医会 宮川病院内科

監修: 平田結喜緒 公益財団法人 兵庫県予防医学協会 健康ライフプラザ

著者校正/監修レビュー済:2024/07/24
参考ガイドライン:
  1. 日本甲状腺学会:甲状腺疾患診断ガイドライン2021
  1. 日本内分泌外科学会、日本甲状腺外科学会:甲状腺腫瘍診療ガイドライン2018. 日本内分泌・甲状腺外科学会雑誌 35:2018
  1. 日本甲状腺学会:バセドウ病治療ガイドライン2019. 南江堂、2019
患者向け説明資料

改訂のポイント:
  1. 定期レビューを行った(変更なし)。

概要・推奨   

  1. 甲状腺結節性病変に対して、超音波上の特徴的な所見を分析することで、良性結節をより的確に診断し、不必要な穿刺吸引細胞診を減らすことができる(推奨度2)
  1. 超音波で悪性を疑う所見としては、縦横比>1(感度40.0%、特異度91.4%)、境界部棘状(感度48.3%、特異度91.8%)、著明な低エコー(感度41.4%、特異度92.2%)、微細石灰化(感度44.2%、特異度90.8%)、粗大石灰化(感度9.7%、特異度96.1%)であった(推奨度2)
  1. 甲状腺ホルモン補充療法は、閉経後の女性では明らかに骨折の頻度が増加させる。甲状腺ホルモン薬による骨量減少は、海綿骨よりも皮質骨で顕著である(推奨度2)

病態・疫学・診察 

疾患情報(疫学・病態)  
  1. 甲状腺腫とは、甲状腺の腫大を認めることである。甲状腺腫は、その原因の特徴により、さらにびまん性病変と結節性病変に分かれ、診察・超音波検査にて鑑別していく。
  1. 甲状腺腫の診断アルゴリズム:図アルゴリズム
病歴・診察のポイント  
  1. びまん性甲状腺腫の場合、 バセドウ病 と 橋本病 、 甲状腺機能低下症 が最も頻度が高いため、臨床症状として甲状腺機能亢進症状(動悸、発汗過多、易疲労感、体重減少、手のふるえ、下痢、情緒不安定など)、あるいは機能低下症状(寒がり、無気力感、皮膚乾燥、むくみ、体重増加、便秘など)がないかどうか、疑って問診する。

これより先の閲覧には個人契約のトライアルまたはお申込みが必要です。

最新のエビデンスに基づいた二次文献データベース「今日の臨床サポート」。
常時アップデートされており、最新のエビデンスを各分野のエキスパートが豊富な図表や処方・検査例を交えて分かりやすく解説。日常臨床で遭遇するほぼ全ての症状・疾患から薬剤・検査情報まで瞬時に検索可能です。

まずは15日間無料トライアル
本サイトの知的財産権は全てエルゼビアまたはコンテンツのライセンサーに帰属します。私的利用及び別途規定されている場合を除き、本サイトの利用はいかなる許諾を与えるものでもありません。 本サイト、そのコンテンツ、製品およびサービスのご利用は、お客様ご自身の責任において行ってください。本サイトの利用に基づくいかなる損害についても、エルゼビアは一切の責任及び賠償義務を負いません。 また、本サイトの利用を以て、本サイト利用者は、本サイトの利用に基づき第三者に生じるいかなる損害についても、エルゼビアを免責することに合意したことになります。  本サイトを利用される医学・医療提供者は、独自の臨床的判断を行使するべきです。本サイト利用者の判断においてリスクを正当なものとして受け入れる用意がない限り、コンテンツにおいて提案されている検査または処置がなされるべきではありません。 医学の急速な進歩に鑑み、エルゼビアは、本サイト利用者が診断方法および投与量について、独自に検証を行うことを推奨いたします。

文献 

Won-Jin Moon, So Lyung Jung, Jeong Hyun Lee, Dong Gyu Na, Jung-Hwan Baek, Young Hen Lee, Jinna Kim, Hyun Sook Kim, Jun Soo Byun, Dong Hoon Lee, Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology
Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study.
Radiology. 2008 Jun;247(3):762-70. doi: 10.1148/radiol.2473070944. Epub 2008 Apr 10.
Abstract/Text PURPOSE: To retrospectively evaluate the diagnostic accuracy of ultrasonographic (US) criteria for the depiction of benign and malignant thyroid nodules by using tissue diagnosis as the reference standard.
MATERIALS AND METHODS: This study had institutional review board approval, and informed consent was waived. From January 2003 through June 2003, 8024 consecutive patients had undergone thyroid US at nine affiliated hospitals. A total of 831 patients (716 women, 115 men; mean age, 49.5 years +/- 13.8 [standard deviation]) with 849 nodules (360 malignant, 489 benign) that were diagnosed at surgery or biopsy were included in this study. Three radiologists retrospectively evaluated the following characteristics on US images: nodule size, presence of spongiform appearance, shape, margin, echotexture, echogenicity, and presence of microcalcification, macrocalcification, or rim calcification. A chi(2) test and multiple regression analysis were performed. Sensitivity, specificity, and positive and negative predictive values were obtained.
RESULTS: Statistically significant (P < .05) findings of malignancy were a taller-than-wide shape (sensitivity, 40.0%; specificity, 91.4%), a spiculated margin (sensitivity, 48.3%; specificity, 91.8%), marked hypoechogenicity (sensitivity, 41.4%; specificity, 92.2%), microcalcification (sensitivity, 44.2%; specificity, 90.8%), and macrocalcification (sensitivity, 9.7%; specificity, 96.1%). The US findings for benign nodules were isoechogenicity (sensitivity, 56.6%; specificity, 88.1%; P < .001) and a spongiform appearance (sensitivity, 10.4%; specificity, 99.7%; P < .001). The presence of at least one malignant US finding had a sensitivity of 83.3%, a specificity of 74.0%, and a diagnostic accuracy of 78.0%. For thyroid nodules with a diameter of 1 cm or less, the sensitivity of microcalcifications was lower than that in larger nodules (36.6% vs 51.4%, P < .05).
CONCLUSION: Shape, margin, echogenicity, and presence of calcification are helpful criteria for the discrimination of malignant from benign nodules; the diagnostic accuracy of US criteria is dependent on tumor size.

(c) RSNA, 2008.
PMID 18403624
John A Bonavita, Jason Mayo, James Babb, Genevieve Bennett, Thaira Oweity, Michael Macari, Joseph Yee
Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone?
AJR Am J Roentgenol. 2009 Jul;193(1):207-13. doi: 10.2214/AJR.08.1820.
Abstract/Text OBJECTIVE: The purpose of this study was to evaluate morphologic features predictive of benign thyroid nodules.
MATERIALS AND METHODS: From a registry of the records of 1,232 fine-needle aspiration biopsies performed jointly by the cytology and radiology departments at a single institution between 2005 and 2007, the cases of 650 patients were identified for whom both a pathology report and ultrasound images were available. From the alphabetized list generated, the first 500 nodules were reviewed. We analyzed the accuracy of individual sonographic features and of 10 discrete recognizable morphologic patterns in the prediction of benign histologic findings.
RESULTS: We found that grouping of thyroid nodules into reproducible patterns of morphology, or pattern recognition, rather than analysis of individual sonographic features, was extremely accurate in the identification of benign nodules. Four specific patterns were identified: spongiform configuration, cyst with colloid clot, giraffe pattern, and diffuse hyperechogenicity, which had a 100% specificity for benignity. In our series, identification of nodules with one of these four patterns could have obviated more than 60% of thyroid biopsies.
CONCLUSION: Recognition of specific morphologic patterns is an accurate method of identifying benign thyroid nodules that do not require cytologic evaluation. Use of this approach may substantially decrease the number of unnecessary biopsy procedures.

PMID 19542415
B Uzzan, J Campos, M Cucherat, P Nony, J P Boissel, G Y Perret
Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis.
J Clin Endocrinol Metab. 1996 Dec;81(12):4278-89. doi: 10.1210/jcem.81.12.8954028.
Abstract/Text Osteoporosis is the main cause of spine and hip fractures. Morbidity, mortality, and costs arising from hip fractures have been well documented. Thyroid hormones (TH) are widely prescribed, mainly in the elderly. Some studies (but not all) found a deleterious effect of suppressive TH therapy on bone mass. These conflicting data raised a controversy as to the safety of current prescribing and follow-up habits, which, in turn, raised major health-care issues. To look for a detrimental effect on bone of TH therapy, we performed a meta-analysis (by pooling standardized differences, using a fixed effect model) of all published controlled cross-sectional studies (41, including about 1250 patients) concerning the impact of TH therapy on bone mineral density (BMD). Studies with women receiving estrogen therapy were excluded a priori, as were studies with a high percentage of patients with postoperative hypoparathyroidism, when no separate data were available. We decided to stratify the data according to anatomical site, menopausal status, and suppressive or replacement TH therapy, resulting in 25 meta-analysis on 138 homogeneous subsets of data. The main sources of heterogensity between studies that we could identify were replacement or suppressive TH therapy, menopausal status, site (lumbar spine, femoral neck, Ward's triangle, greater trochanter, midshaft and distal radius, with various percentages of cortical bone), and history of hyperthyroidism, which has recently been found to impair bone mass in a large epidemiological survey. To improve homogeneity, we excluded a posteriori 102 patients from 3 studies, who had a past history of hyperthyroidism and separate BMD data, thus allowing assessment of the TH effect in almost all 25 subset meta-analyses. However, controls were usually not matched with cases for many factors influencing bone mass, such as body weight, age at menarche and at menopause, calcium dietary intake, smoking habits, alcohol intake, exercise, etc. For lumbar spine and hip (as for all other sites), suppressive TH therapy was associated with significant bone loss in postmenopausal women (but not in premenopausal women), whereas, conversely, replacement therapy was associated with bone loss in premenopausal women (spine and hip), but not in postmenopausal women. The detrimental effect of TH appeared more marked on cortical bone than on trabecular bone. Only a large long term prospective placebo-controlled trial of TH therapy (e.g. in benign nodules) evaluating BMD (and ideally fracture rate) would provide further insight into these issues.

PMID 8954028
薬剤監修について:
オーダー内の薬剤用量は日本医科大学付属病院 薬剤部 部長 伊勢雄也 以下、渡邉裕次、井ノ口岳洋、梅田将光および日本医科大学多摩永山病院 副薬剤部長 林太祐による疑義照会のプロセスを実施、疑義照会の対象については著者の方による再確認を実施しております。
※薬剤中分類、用法、同効薬、診療報酬は、エルゼビアが独自に作成した薬剤情報であり、 著者により作成された情報ではありません。
尚、用法は添付文書より、同効薬は、薬剤師監修のもとで作成しております。
※同効薬・小児・妊娠および授乳中の注意事項等は、海外の情報も掲載しており、日本の医療事情に適応しない場合があります。
※薬剤情報の(適外/適内/⽤量内/⽤量外/㊜)等の表記は、エルゼビアジャパン編集部によって記載日時にレセプトチェックソフトなどで確認し作成しております。ただし、これらの記載は、実際の保険適応の査定において保険適応及び保険適応外と判断されることを保証するものではありません。また、検査薬、輸液、血液製剤、全身麻酔薬、抗癌剤等の薬剤は保険適応の記載の一部を割愛させていただいています。
(詳細はこちらを参照)
著者のCOI(Conflicts of Interest)開示:
宮川めぐみ : 特に申告事項無し[2025年]
監修:平田結喜緒 : 特に申告事項無し[2025年]

ページ上部に戻る

甲状腺腫

戻る